EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.

US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.

Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.

Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.

The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).

CRISPR Therapeutics and Vertex received approval from the UK's MHRA for the initial gene-edited treatment, CASGEVY™ (exagamglogene autotemcel), targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia employing CRISPR/Cas9 technology.

Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.

Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.

Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.

Kyverna Therapeutics reveals FDA approval for Phase 2 study of KYV-101, a complete human CD19 CAR T-Cell treatment for Myasthenia Gravis.